Genpine Biologics Wins U.S. Invention Patent, TCR-enriched Clonotype Technology Helps Immunotherapy R&D Make New Breakthroughs!
On March 18, 2025, Source Bio ushered in a milestone moment - the independently developed “TCR-enriched clonotype, acquisition method and use thereof” was formally granted by the United States Patent and Trademark Office (Patent No. TCR-enriched clonotype and its acquisition method and use thereof). TCR-enriched clonotype, acquisition method and use thereof” was officially authorized by the United States Patent and Trademark Office (Patent No. US 12,252,526B2). The approval of this patent signifies that Chinese enterprises have achieved global leadership in the field of T-cell receptor (TCR) technology, which provides a new theoretical basis and technical support for global immunotherapy research and development.
TCR-enriched clonogenic technology: a new engine for immunotherapy research and development
TCR (T-cell receptor) is a key molecule in the immune system for recognizing antigens, and its diversity determines the specific recognition ability of the immune system for antigens. Through in-depth study of the immune response of patients with cured viral infections, Genpine Biologics has successfully obtained a TCR-enriched cloned amino acid sequence that is enriched in effector CD8+ T cells and CD4+ memory T cell clusters. This sequence is capable of specifically recognizing antigenic epitopes through the shared CDR3 variable region, providing an important research direction for immunotherapy development.
This technological breakthrough not only highlights Genpine Bio's technological leadership in the field of immune cells, but also lays a solid foundation for personalized immunotherapy design and precision immunotherapy. In the future, TCR-enriched cloning technology is expected to play an important role in the immunotherapy of infectious diseases and cancers, and promote the global immunotherapy research and development into a new stage.
Source Bio: Driven by Innovation, Leading the Cell Therapy Industry
As a leading company in the field of cell therapy, Yuanpin Bio has always insisted on technological innovation as the core driving force. At present, the company has owned and applied for more than 40 international/domestic patents and more than 20 core proprietary technologies, covering the key technologies of the cell therapy industry chain, showing strong R&D strength and innovation ability. Relying on its independent innovation platform, the company is accelerating the R&D and clinical transformation of multi-pipeline cellular drugs, and has achieved a number of milestone breakthroughs in the fields of respiratory system, sports medicine, reproductive health and tumor immunity.
Future Prospect: Empowering the high-quality development of cell therapy
In the future, Genpine Bio will continue to deepen its technological innovation and empower the high-quality development of the cell therapy industry. The company will continue to increase industrial chain innovation, deepen key technology research, promote intelligent, large-scale preparation process upgrading, accelerate the clinical transformation and industrialization process, to meet the urgent needs of the domestic market for cell therapy, and to contribute more power to the cause of human health. At the same time, the company will also promote the global sharing of technical achievements with an international perspective, contributing Chinese wisdom and Chinese power to the global health cause.
